These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 7146829)
1. Immunity against Francisella tularensis in northern Finland. Koskela P; Herva E Scand J Infect Dis; 1982; 14(3):195-9. PubMed ID: 7146829 [TBL] [Abstract][Full Text] [Related]
2. Cell-mediated immunity against Francisella tularensis after natural infection. Koskela P; Herva E Scand J Infect Dis; 1980; 12(4):281-7. PubMed ID: 7006062 [TBL] [Abstract][Full Text] [Related]
3. [Serum immunoglobulin IgG subclass distribution of antibody responses to Francisella tularensis in patients with tularemia]. Rastawicki W; Rokosz-Chudziak N; Wolaniuk N Med Dosw Mikrobiol; 2014; 66(1):11-5. PubMed ID: 25007508 [TBL] [Abstract][Full Text] [Related]
4. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. Ericsson M; Sandström G; Sjöstedt A; Tärnvik A J Infect Dis; 1994 Jul; 170(1):110-4. PubMed ID: 8014484 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 production in whole blood culture: a rapid test of immunity to Francisella tularensis. Karttunen R; Ilonen J; Herva E J Clin Microbiol; 1985 Aug; 22(2):318-9. PubMed ID: 3875626 [TBL] [Abstract][Full Text] [Related]
6. Antigen from Francisella tularensis: nonidentity between determinants participating in cell-mediated and humoral reactions. Sandström G; Tärnvik A; Wolf-Watz H; Löfgren S Infect Immun; 1984 Jul; 45(1):101-6. PubMed ID: 6203835 [TBL] [Abstract][Full Text] [Related]
7. [Prevalence of antibodies against Francisella tularensis in Castilla y León (Spain) before 1997]. Gutiérrez MP; Orduña A; Dueñas A; Bratos MA; Almaraz A; Alamo R; Rodríguez Recio MJ; Rodríguez Marcos H; Rodríguez Torres A Med Clin (Barc); 2003 Feb; 120(3):97-8. PubMed ID: 12605730 [TBL] [Abstract][Full Text] [Related]
8. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Kirimanjeswara GS; Olmos S; Bakshi CS; Metzger DW Immunol Rev; 2008 Oct; 225():244-55. PubMed ID: 18837786 [TBL] [Abstract][Full Text] [Related]
9. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. KuoLee R; Harris G; Conlan JW; Chen W Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863 [TBL] [Abstract][Full Text] [Related]
10. Nature of protective immunity to Francisella tularensis. Tärnvik A Rev Infect Dis; 1989; 11(3):440-51. PubMed ID: 2665002 [TBL] [Abstract][Full Text] [Related]
11. Humoral immunity induced by a live Francisella tularensis vaccine. Complement fixing antibodies determined by an enzyme-linked immunosorbent assay (CF-ELISA). Koskela P Vaccine; 1985 Dec; 3(5):389-91. PubMed ID: 4082752 [TBL] [Abstract][Full Text] [Related]
12. [Tularemia seroprevalence in the risky population living in both rural and urban areas of Erzurum]. Yazgı H; Uyanık MH; Ertek M; Kılıç S; Kireçci E; Ozden K; Ayyıldız A Mikrobiyol Bul; 2011 Jan; 45(1):67-74. PubMed ID: 21341161 [TBL] [Abstract][Full Text] [Related]
13. Time of lymphocyte response after onset of tularemia and after tularemia vaccination. Tärnvik A; Sandström G; Löfgren S J Clin Microbiol; 1979 Dec; 10(6):854-60. PubMed ID: 521485 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model. Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073 [TBL] [Abstract][Full Text] [Related]
15. Adaptive Immunity to Roberts LM; Powell DA; Frelinger JA Front Cell Infect Microbiol; 2018; 8():115. PubMed ID: 29682484 [No Abstract] [Full Text] [Related]
16. Immunological markers that correlate with protection immunity against tularemia infection. Firstova VV; Mokrievich AN; Pavlov VM; Gorbatov AA; Kombarova TI; Biketov SF; Dyatlov IA Adv Exp Med Biol; 2014; 808():15-23. PubMed ID: 24595607 [TBL] [Abstract][Full Text] [Related]
17. [Comparative study of the basic immunological reactions for assessing tularemia immunity in inoculated persons or those who have had the disease]. Kamennova LS; Pokrovskaia VI; Vasil'eva VP; Petrova LI; Liubomudrov VB Zh Mikrobiol Epidemiol Immunobiol; 1983 Nov; (11):92-5. PubMed ID: 6659772 [TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754 [TBL] [Abstract][Full Text] [Related]
19. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Drabick JJ; Narayanan RB; Williams JC; Leduc JW; Nacy CA Am J Med Sci; 1994 Aug; 308(2):83-7. PubMed ID: 8042659 [TBL] [Abstract][Full Text] [Related]
20. Vaccine-Mediated Mechanisms Controlling Replication of Eneslätt K; Golovliov I; Rydén P; Sjöstedt A Front Cell Infect Microbiol; 2018; 8():27. PubMed ID: 29468144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]